Cidara Therapeutics Inc (CDTX) Company Profile & Statistics

Cidara Therapeutics Inc
CDTX
(Nasdaq - US)
Closed
20.68
+3.23 (+18.51%)
in:usd•As of: Nov 22, 2024 15:58 UTC -5
After Market:20.82+0.14 (+0.68%)
Open
19.60
High
20.69
Low
18.46

About Cidara Therapeutics Inc

CEO

Jeffrey Stein

Headquarters

6310 nancy ridge drive, suite 101

san diego, ca 92121, united states

Auditor

Ernst & Young LLP

Employees

Share Holders

Website

www.cidara.com

Industry

pharmaceuticals other

Sector

health technology

Company Overview

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.

Cidara Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	145.79M
Enterprise Value	18.67M
Enterprise Value/EBITDA (ttm)	-0.13
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	0.95
Price to Sales (ttm)	2.82
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	68.76%
Operating Margin (ttm)	-79.45%
Profit Margin (ttm)	-7583.66%
Return on Equity (ttm)	-69.64%
Return on Invested Capital (ttm)	167.04%
Return on Assets (ttm)	-33.73%

Income Statement

Revenue (ttm)	32.26M
Revenue Per Share (ttm)	4.58
Gross Profit (ttm)	29.17M
EBITDA (ttm)³	-139.70M
Net Income Avi to Common (ttm)	-120.10M
Diluted EPS (ttm)	-25.52

Share Statistics

Beta (5Y Monthly)	0.99
52-Week Change	38.05%
S&P500 52-Week Change	31.00%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	7.05M
Dividend Yield	0.00%
Float ⁴	6.51M
% Held by Insiders	7.64%
% Held by Institutions	35.82%

Balance Sheet

Total Cash (mrq)	127.39M
Total Cash Per Share (mrq)	18.08
Total Debt (mrq)	259.00K
Total Debt/Equity (mrq)	0.22%
Current Ratio (mrq)	3.54%
Quick Ratio (mrq)	3.54%
Book Value Per Share (mrq)	16.41

Cash Flow

Operating Cash Flow Per Share (ytd)	-22.53
Free Cash Flow (ytd)	-147.25M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Cidara Therapeutics Inc

Trade With A Regulated Broker